LU91756I2 - Denosumab - Google Patents

Denosumab

Info

Publication number
LU91756I2
LU91756I2 LU91756C LU91756C LU91756I2 LU 91756 I2 LU91756 I2 LU 91756I2 LU 91756 C LU91756 C LU 91756C LU 91756 C LU91756 C LU 91756C LU 91756 I2 LU91756 I2 LU 91756I2
Authority
LU
Luxembourg
Prior art keywords
reagents
antigen
denosumab
mammal
nucleic acids
Prior art date
Application number
LU91756C
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21867133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91756(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of LU91756I2 publication Critical patent/LU91756I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
LU91756C 1996-12-13 2010-11-24 Denosumab LU91756I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3284696P 1996-12-13 1996-12-13
EP97953164A EP0948530A2 (fr) 1996-12-13 1997-12-12 Antigenes de surface de cellules de mammiferes

Publications (1)

Publication Number Publication Date
LU91756I2 true LU91756I2 (fr) 2011-01-24

Family

ID=21867133

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91756C LU91756I2 (fr) 1996-12-13 2010-11-24 Denosumab

Country Status (14)

Country Link
US (5) US6242586B1 (fr)
EP (5) EP1114864B9 (fr)
JP (6) JP2001506991A (fr)
CN (1) CN1245534A (fr)
AT (1) ATE399861T1 (fr)
AU (1) AU5697098A (fr)
BR (1) BR9714401A (fr)
CA (1) CA2274801C (fr)
DE (2) DE122010000046I1 (fr)
DK (1) DK1114864T4 (fr)
ES (1) ES2305009T5 (fr)
LU (1) LU91756I2 (fr)
PT (1) PT1114864E (fr)
WO (1) WO1998025958A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
WO1999058674A2 (fr) * 1998-05-14 1999-11-18 Immunex Corporation Procede pour inhiber l'activite osteoclastique
ATE497001T1 (de) 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
JP3523650B2 (ja) * 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6084926A (en) * 1997-12-08 2000-07-04 Ericsson Inc. Method and system for demodulating radio signals
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
EP1541587A3 (fr) * 1998-09-15 2007-06-20 Pharmexa A/S Méthode pour diminuer l'activité du ligand de l'ostéoprotégérine
HRP20010188A2 (en) 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
WO2001062932A1 (fr) † 2000-02-23 2001-08-30 Amgen Inc. Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
TR201809678T4 (tr) 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 ｔｎｆ-펩티드의 담체 콘쥬게이트의 의학적 용도
US7582910B2 (en) * 2005-02-28 2009-09-01 The Regents Of The University Of California High efficiency light emitting diode (LED) with optimized photonic crystal extractor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
EP0088994B1 (fr) 1982-03-15 1991-06-19 Schering Corporation ADN hybride, composition liante produite à l'aide de celui-ci et procédés pour la mise en oeuvre
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
ES2118372T3 (es) 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
CA2217641A1 (fr) * 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides presentant un domaine fonctionnel important, et leurs procedes d'identification et d'utilisation
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6111090A (en) * 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
WO1999058674A2 (fr) * 1998-05-14 1999-11-18 Immunex Corporation Procede pour inhiber l'activite osteoclastique
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
JP3523650B2 (ja) * 1997-04-15 2004-04-26 三共株式会社 新規蛋白質及びその製造方法
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins

Also Published As

Publication number Publication date
ATE399861T1 (de) 2008-07-15
JP2008143906A (ja) 2008-06-26
EP1995317B1 (fr) 2014-11-05
US20030144480A1 (en) 2003-07-31
JP2013074899A (ja) 2013-04-25
EP1114864B1 (fr) 2008-07-02
EP1114864A3 (fr) 2001-10-10
CN1245534A (zh) 2000-02-23
JP2010119397A (ja) 2010-06-03
EP1114864A2 (fr) 2001-07-11
EP1995317A1 (fr) 2008-11-26
DK1114864T3 (da) 2008-10-06
EP0948530A2 (fr) 1999-10-13
WO1998025958A3 (fr) 1998-07-30
WO1998025958A2 (fr) 1998-06-18
US6525180B1 (en) 2003-02-25
CA2274801A1 (fr) 1998-06-18
DK1114864T4 (da) 2012-09-03
HK1034743A1 (en) 2001-11-02
AU5697098A (en) 1998-07-03
US6242586B1 (en) 2001-06-05
EP1803816A2 (fr) 2007-07-04
JP2001506991A (ja) 2001-05-29
EP1803816A3 (fr) 2007-09-26
ES2305009T3 (es) 2008-11-01
JP2009254381A (ja) 2009-11-05
DE69738811D1 (de) 2008-08-14
BR9714401A (pt) 2000-04-18
ES2305009T5 (es) 2012-11-15
US7063841B2 (en) 2006-06-20
US20060025572A1 (en) 2006-02-02
EP1114864B9 (fr) 2013-05-08
PT1114864E (pt) 2008-10-08
DE122010000046I1 (de) 2011-05-05
EP1995318A1 (fr) 2008-11-26
US20090092597A1 (en) 2009-04-09
EP1114864B2 (fr) 2012-07-25
JP2010172336A (ja) 2010-08-12
CA2274801C (fr) 2014-02-04

Similar Documents

Publication Publication Date Title
ATE397660T1 (de) Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
BR9714401A (pt) Antìgenos de supefìcie de célula de mamìfero; regentes relacionados
WO1998027114A3 (fr) Antigenes de surface mammaliens et reactifs associes
MY157028A (en) Mammalian cytokine, related reagents
WO1995018826A3 (fr) Antigenes a ctla-8 de primates purifiee et reactifs correspondants
WO1997021812A3 (fr) Chemokine mammifere ccf8 et recepteur de chemokine cckr3
ATE456656T1 (de) Isolierte gene aus säuger monozyten und betreffende reagentien
WO1998011226A3 (fr) Chemokines de mammiferes et reactifs apparentes
ATE389018T1 (de) Cx3c chemokin-gene von säugetieren
ATE265533T1 (de) Saeugetierchemokine
WO1998039421A3 (fr) Proteinase mammaliennes, oxydoreductase, proteines de liaison avec gtp et reactifs correspondants
WO1998032858A3 (fr) Chemokines de mammiferes, recepteurs, reactifs, et modes d'utilisation
ATE294237T1 (de) S?ugetier thymokingene
EP0997476A3 (fr) Anticorps contre un antigène de cellules Langerhans mammifères et leurs utilisations
WO1999047673A3 (fr) Genes de proteines membranaires mammiferes isoles, et reactifs associes
WO1998031810A3 (fr) Chemokines de mammiferes, recepteurs, reactifs, utilisations
EP1867720A3 (fr) Antigènes de surface des cellules des mammifères à codage génétique purifié ; protéines et anticorps
WO2000034335A3 (fr) Genes mammiferes et reactifs connexes
WO1999019491A3 (fr) Interleukine-40 adnx humaine (dil-40)
WO2001009176A3 (fr) Cytokines mammaliennes; reactifs correspondants
WO1998023747A3 (fr) Genes isoles de cellules dendritiques de mammiferes et reactifs correspondants
CA2264963A1 (fr) Marqueur proteique pour cancer de l'oesophage